Department of Radiation Oncology and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
J Thorac Oncol. 2011 Jul;6(7):1282-6. doi: 10.1097/JTO.0b013e31821f9662.
We assessed the efficacy of adjuvant radiotherapy (RT) in patients with stage II or III thymoma and evaluated the prognostic factors after the treatment.
The medical records of 76 patients with completely resected stage II (n = 65) or III (n = 11) thymoma treated at a single institution within the period from November 1988 to February 2009 were retrospectively reviewed. Seventeen patients were treated with surgery only (group A), and 59 patients received adjuvant RT after surgery (group B). The median radiation dose was 50 Gy (range: 43.2-66 Gy). The prognostic factors, such as age, myasthenia gravis symptom, tumor size, staging, adjuvant RT, and radiation dose, were analyzed. The median follow-up time was 58.5 months (range: 6-231 months).
The 5- to 10-year overall survival and disease-free survival (DFS) rates were 95.3% and 83.8% and 91.5% and 82.5%, respectively. The 5- and 10-year DFS (80% and 70% and 97.8% and 92.7% in groups A and B, respectively; p = 0.043), and the median time to recurrence (37.4 and 50.6 months in groups A and B, respectively) was statistically different between groups A and B.
Masaoka staging and adjuvant RT were related to DFS in completely resected stage II or III thymoma. Based on this study, adjuvant RT will be beneficial in this clinical setting.
我们评估了辅助放疗（RT）在 II 期或 III 期胸腺瘤患者中的疗效，并评估了治疗后的预后因素。
回顾性分析了 1988 年 11 月至 2009 年 2 月期间在一家机构接受完全切除的 II 期（n = 65）或 III 期（n = 11）胸腺瘤治疗的 76 例患者的病历。17 例患者仅接受手术治疗（A 组），59 例患者术后接受辅助 RT（B 组）。中位放疗剂量为 50Gy（范围：43.2-66Gy）。分析了年龄、重症肌无力症状、肿瘤大小、分期、辅助 RT 和放疗剂量等预后因素。中位随访时间为 58.5 个月（范围：6-231 个月）。
5-10 年总生存率和无病生存率（DFS）分别为 95.3%和 83.8%，91.5%和 82.5%。5 年和 10 年 DFS（A 组和 B 组分别为 80%和 70%，97.8%和 92.7%；p = 0.043）以及 A 组和 B 组的中位复发时间（分别为 37.4 个月和 50.6 个月）在组间存在统计学差异。
Masaoka 分期和辅助 RT 与完全切除的 II 期或 III 期胸腺瘤的 DFS 相关。基于这项研究，辅助 RT 在这种临床环境下是有益的。
